A new effective Staphylococcus aureus vaccine for mastitis
| Reference number | |
| Coordinator | Savacc AB |
| Funding from Vinnova | SEK 890 000 |
| Project duration | May 2019 - November 2021 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups stage 2 - spring 2019 |
Important results from the project
It is the intention to publish the result. So far the 3 vaccinations carried out in cows have resulted in excellent antibody responses in serum and milk. A field trial has started with the test vaccine including 125 cows and 125 control animals. The goal is an immune protective SA vaccine
Expected long term effects
The test vaccine Chrivacc has induced high antibody levels in blood serum and milk in cows so far lasting over the test period. It is expected dat protective immunity will be achieved. The present vaccine will be tested over a period of 2 years
Approach and implementation
125 cows are vaccinated with the Swedish SA vaccine and compared to antibody responses in serum and milk with a control SA vaccine (also 125 cows). They are designated for a natural infection The trial continues for more than a year. Antibody levels are analyzed after one and two immunizations and the protection against infection and disease through clinical monitoring, bacteriological samples taken at SVA. The antibody levels in serum and milk are monitored continuously. The results regarding immune response will come from now on.